Canine Congestive Heart Failure (CHF): Complete NAVLE Study Guide
Canine CHF shows up on the NAVLE constantly, and it almost always comes down to three things: knowing your breeds, knowing your staging, and knowing your drugs. Get those right and you'll handle whatever question they throw at you.
The Two Main Causes
MMVD
Myxomatous Mitral Valve Disease
Breeds: CKCS, Poodles, Dachshunds, small breeds
Mechanism: Valve thickening → MR → LA enlargement
FS: Usually preserved (>25%)
~75% of canine cardiac disease
DCM
Dilated Cardiomyopathy
Breeds: Doberman, Great Dane, Boxer, Irish Wolfhound
Mechanism: Myocardium dilates → poor contractility
FS: Reduced (<25%)
Occult phase common in Dobermans
ACVIM Staging — Know This Cold
The 2019 ACVIM Consensus Guidelines divided MMVD into four stages. The boards test whether you know when to start treatment — not just which drugs to use.
The EPIC trial (2016) changed everything for Stage B2. Before EPIC, you waited until CHF to start pimobendan. Now you start it in asymptomatic dogs with significant remodeling — it delays onset of CHF by about 15 months. That finding is highly testable.
Clinical Signs: Left vs Right-Sided
Left-Sided Failure
• Soft, moist cough (worse at night)
• Exercise intolerance
• Tachypnea, orthopnea
• Pulmonary crackles
Rads: perihilar pulmonary edema
Right-Sided Failure
• Ascites
• Pleural effusion (less common in dogs)
• Jugular venous distension
• Hepatomegaly, peripheral edema
Rads: hepatomegaly + ascites
Diagnostics
Thoracic radiographs — first step in respiratory distress. Look for cardiomegaly (VHS >10.5), left atrial enlargement on lateral view (the caudal cardiac waist disappears), and perihilar alveolar pattern for pulmonary edema.
Echocardiography — gold standard for staging. Gives you LA:Ao ratio, fractional shortening (FS), and confirms structural disease. FS <25% = systolic dysfunction in dogs.
NT-proBNP — rises with myocardial wall stretch. Useful to differentiate cardiac from respiratory dyspnea before echo is available. The QUEST trial validated its use in MMVD.
Holter monitor — 24h ECG. Standard Doberman DCM screening. >300 VPCs/24h = clinically significant.
Treatment Drugs at a Glance
Prognosis
Stage B2 dogs started on pimobendan: median time to CHF onset ~3 years. Stage C with optimal therapy: median survival 9–12 months. Stage D: weeks to a few months.
Atrial fibrillation in a Doberman with DCM = emergency. Rate control with diltiazem or digoxin + aggressive diuresis. AFib significantly shortens survival in large breed DCM.
Quick Reference
- MMVD = small breeds (CKCSs); DCM = large breeds (Dobermans)
- Stage B2 criteria: LA:Ao ≥1.6 AND VHS ≥10.5 → start pimobendan (EPIC trial)
- Acute CHF: furosemide 2–4 mg/kg IV + oxygen
- Chronic: furosemide + pimobendan + ACE inhibitor ± spironolactone
- Pimobendan: empty stomach, BID
- Left CHF = pulmonary edema; Right CHF = ascites/JVD
- NT-proBNP differentiates cardiac vs respiratory dyspnea
- Holter monitor Dobermans: >300 VPCs/24h = significant
- FS <25% = systolic dysfunction (DCM territory)
Practice NAVLE Questions
Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.
Start Your Free Trial →